Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
Pharmaceutical Technology on MSN
Moderna signs deal worth up to $503m with Nanexa
Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...
Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback